Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Power List / 2022 / Advanced Medicine / Chris van der Walle

Chris van der Walle

Edinburgh Centre Director, Cell & Gene Therapy Catapult

  • Profile

Meet Chris van der Walle

Van der Walle obtained his PhD in peptide chemistry from King’s College London. At the beginning of 2022 he became the Edinburgh Centre Director of the Cell & Gene Therapy Catapult, where he switched his focus to scientific and industrial collaboration, technology transfer, and clinical trial acceleration. He has published over 100 research articles, reviews, and book chapters and retains an interest in pharmaceutics and advanced therapy medicinal products.

What is the most interesting or little-known fact about you?

I can’t run, so I stick to cycling for exercise and relaxation.

What’s been the biggest breakthrough in cell & gene in recent years?

The public perception and widespread acceptance of vaccines based on messenger RNA delivered in tiny lipid globules, and the speed at which they can be progressed from lab to clinic.

False

Advertisement

Recommended

False

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.